TY - JOUR
AU - Taylor, Stephanie, N.
AB - Downloaded from http://journals.lww.com/stdjournal by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/02/2020 NOTE x x Performance of the BD CTQ and GCQ Amplified Assays on the BD Viper LT Compared With the BD Viper XTR System Barbara Van Der Pol, PhD, MPH,* Edward W. Hook, III, MD,* James A. Williams, BS,† Bonnie Smith, WHNP,‡ and Stephanie N. Taylor, MD§ to screening is limited due to a lack of local testing options. Most Abstract: We evaluated the BD Viper LT System for detection of Chla- of the diagnostic platforms that offer chlamydia and gonorrhea mydia trachomatis and Neisseria gonorrhoeae using samples collected screening use medium high to high-volume (e.g., >96 samples/d) from symptomatic patients that included urine, vaginal swabs, and cervical throughput analyzers requiring a substantial capital investment for samples in liquid-based cytology media. Results were compared with those instruments for specialty diagnostic menus. As a result, smaller obtained using the BD Viper XTR platform. The positive and negative per- health care settings often refer samples to large tertiary care facil- cent agreements for all sample types were at least 95.8% and at least 96.4% ities or commercial laboratories for testing. Options that can for chlamydia and gonorrhea and at least 95.0% when both organisms 
TI - Performance of the BD CTQx and GCQx Amplified Assays on the BD Viper LT Compared With the BD Viper XTR System
JF - Sexually Transmitted Diseases
DO - 10.1097/OLQ.0000000000000313
DA - 2015-09-01
UR - https://www.deepdyve.com/lp/wolters-kluwer-health/performance-of-the-bd-ctqx-and-gcqx-amplified-assays-on-the-bd-viper-H0n8aX34op
SP - 521
VL - 42
IS - 9
DP - DeepDyve
ER -